识别异烟肼耐药标志物以指导结核治疗方案中高剂量异烟肼的纳入
该系统综述检索PubMed、Web of Science和Embase,纳入46项报告临床结核分枝杆菌分离株基因型与表型数据及异烟肼耐药水平的研究,共1697株分离株。结果显示katG基因变异仅当位于 codon 315 时才是高水平异烟肼耐药的良好标志物。
要点
- katG codon 315 变异者93%为高水平异烟肼耐药。
- katG非315位变异者仅50%为高水平耐药。
- katG野生型但含其他相关变异者40%为高水平耐药。
核心结论
- katG基因变异仅当位于 codon 315 时才是高水平异烟肼耐药的良好标志物。
研究设计与样本
- 系统文献综述,检索PubMed、Web of Science和Embase,纳入46项报告临床分离株基因型与表型数据及异烟肼耐药水平的研究,共1697株分离株。
主要发现
- 1697株分离株中21%(n=362)为异烟肼敏感,17%(n=287)为低水平耐药,62%(n=1048)为高水平耐药。
- 24%(n=402)的分离株为野生型,76%(n=1295)具有至少一个相关遗传变异。
- 1295株具有至少一个变异的分离株中,78%(n=1011)存在katG基因突变。
- 867株katG codon 315 突变的分离株中,93%(n=810)为高水平异烟肼耐药;144株katG非315位变异的分离株中,仅50%(n=72)为高水平耐药。
- 284株具有至少一个相关遗传变异且katG野生型的分离株中,40%(n=114)为高水平异烟肼耐药。
关键数值与推荐
- 低水平异烟肼耐药定义:液体培养基MIC 0.1-0.4 μg/mL,固体培养基0.2-1.0 μg/mL;高水平耐药定义:液体培养基MIC >0.4 μg/mL,固体培养基>1.0 μg/mL。
临床怎么用
- 检测katG codon 315 变异有助于识别高水平异烟肼耐药,指导高剂量异烟肼的合理使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Effective use of antibiotics is critical to control the global tuberculosis pandemic. High-dose isoniazid (INH) can be effective in the presence of low-level resistance. We performed a systematic literature review to improve our understanding of the differential impact of genomic Mycobacterium tuberculosis (Mtb) variants on the level of INH resistance. The following online databases were searched: PubMed, Web of Science and Embase. Articles reporting on clinical Mtb isolates with linked genotypic and phenotypic data and reporting INH resistance levels were eligible for inclusion. METHODS: All genomic regions reported in the eligible studies were included in the analysis, including: katG, inhA, ahpC, oxyR-ahpC, furA, fabG1, kasA, rv1592c, iniA, iniB, iniC, rv0340, rv2242 and nat. The level of INH resistance was determined by MIC: low-level resistance was defined as 0.1-0.4 μg/mL on liquid and 0.2-1.0 μg/mL on solid media, high-level resistance as >0.4μg/mL on liquid and >1.0 μg/mL on solid media. RESULTS: A total of 1212 records were retrieved of which 46 were included. These 46 studies reported 1697 isolates of which 21% (n = 362) were INH susceptible, 17% (n = 287) had low-level, and 62% (n = 1048) high-level INH resistance. Overall, 24% (n = 402) of isolates were reported as wild type and 76% (n = 1295) had ≥1 relevant genetic variant. Among 1295 isolates with ≥1 variant, 78% (n = 1011) had a mutation in the katG gene. Of the 867 isolates with a katG mutation in codon 315, 93% (n = 810) had high-level INH resistance. In contrast, only 50% (n = 72) of the 144 isolates with a katG variant not in the 315-position had high-level resistance. Of the 284 isolates with ≥1 relevant genetic variant and wild type katG gene, 40% (n = 114) had high-level INH resistance. CONCLUSIONS: Presence of a variant in the katG gene is a good marker of high-level INH resistance only if located in codon 315.
引用
- Rivière E, Whitfield MG, Nelen J, et al. Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens. Clin Microbiol Infect. 2020. PMID: 32653663. doi:10.1016/j.cmi.2020.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。